Book contents
- Frontmatter
- Contents
- Contributors
- Progress in Neurotherapeutics and Neuropsychopharmacology 2008
- Triflusal versus Aspirin for the Prevention of Stroke
- The Argatroban and tPA Stroke Study
- Use of Selegiline as Monotherapy and in Combination with Levodopa in the Management of Parkinson's Disease: Perspectives from the MONOCOMB Study
- Ropinirole 24-h Prolonged Release in Advanced Parkinson Disease: Review of a Randomized, Double-Blind, Placebo-Controlled Study (EASE PD-Adjunct Study)
- Insulin Resistance Alzheimer's Disease: Pathophysiology and Treatment
- Targeting Amyloid with Tramiprosate in Patients with Mild-to-Moderate Alzheimer Disease
- Intranasal Zolmitriptan Is Effective and Well Tolerated in Acute Cluster Headache: A Randomized Placebo-Controlled Double-Blind Crossover Study
- Optimal Dosing of Immunomodulating Drugs: A Dose-Comparison Study of GA in RRMS
- Tetrathiomolybdate versus Trientine in the Initial Treatment of Neurologic Wilson's Disease
- Randomized Clinical Trials of Pregabalin for Neuropathic Pain: Methods, Results, and Implications
- Effect of Methylphenidate in Patients with Acute Traumatic Brain Injury; a Randomized Clinical Trial
- Improvement in Speeded Cognitive Processing After Anti-epileptic Drug Withdrawal–A Controlled Study in Mono-therapy Patients
- A Randomized-Controlled Trial of Bilateral rTMS for Treatment-Resistant Depression
- Serotonin Related Genes Affect Antidepressant Treatment in Obsessive–Compulsive Disorder
- Night Eating Syndrome and Results from the First Placebo-Controlled Trial of Treatment, with the SSRI Medication, Sertraline: Implications for Clinical Practice
- Modafinil: A Candidate for Pharmacotherapy of Negative Symptoms in Schizophrenia
- New Approaches to Treatment of Schizophrenia by Enhancing N-methyl-D-aspartate Neurotransmission
- Subject Index
- Author Index
Triflusal versus Aspirin for the Prevention of Stroke
Published online by Cambridge University Press: 13 May 2010
- Frontmatter
- Contents
- Contributors
- Progress in Neurotherapeutics and Neuropsychopharmacology 2008
- Triflusal versus Aspirin for the Prevention of Stroke
- The Argatroban and tPA Stroke Study
- Use of Selegiline as Monotherapy and in Combination with Levodopa in the Management of Parkinson's Disease: Perspectives from the MONOCOMB Study
- Ropinirole 24-h Prolonged Release in Advanced Parkinson Disease: Review of a Randomized, Double-Blind, Placebo-Controlled Study (EASE PD-Adjunct Study)
- Insulin Resistance Alzheimer's Disease: Pathophysiology and Treatment
- Targeting Amyloid with Tramiprosate in Patients with Mild-to-Moderate Alzheimer Disease
- Intranasal Zolmitriptan Is Effective and Well Tolerated in Acute Cluster Headache: A Randomized Placebo-Controlled Double-Blind Crossover Study
- Optimal Dosing of Immunomodulating Drugs: A Dose-Comparison Study of GA in RRMS
- Tetrathiomolybdate versus Trientine in the Initial Treatment of Neurologic Wilson's Disease
- Randomized Clinical Trials of Pregabalin for Neuropathic Pain: Methods, Results, and Implications
- Effect of Methylphenidate in Patients with Acute Traumatic Brain Injury; a Randomized Clinical Trial
- Improvement in Speeded Cognitive Processing After Anti-epileptic Drug Withdrawal–A Controlled Study in Mono-therapy Patients
- A Randomized-Controlled Trial of Bilateral rTMS for Treatment-Resistant Depression
- Serotonin Related Genes Affect Antidepressant Treatment in Obsessive–Compulsive Disorder
- Night Eating Syndrome and Results from the First Placebo-Controlled Trial of Treatment, with the SSRI Medication, Sertraline: Implications for Clinical Practice
- Modafinil: A Candidate for Pharmacotherapy of Negative Symptoms in Schizophrenia
- New Approaches to Treatment of Schizophrenia by Enhancing N-methyl-D-aspartate Neurotransmission
- Subject Index
- Author Index
Summary
ABSTRACT
Antiplatelet agents represent an important part of the therapeutic armamentarium in the prevention of stroke. Triflusal is an antiplatelet agent structurally related to salicylates but not derived from acetylsalicylic acid. Like aspirin, triflusal irreversibly acetylates cyclo-oxygenase isoform 1 (COX-1) and therefore inhibits thromboxane biosynthesis. Triflusal is rapidly absorbed after oral administration, with an absorption half life of 0.44 hours. Evidence of the efficacy and safety of triflusal is derived from clinical trials performed in patients with unstable angina, acute myocardial infarction, stroke, aortocoronary bypass, atrial fibrillation, valve replacement, and asthmatic patients intolerant to aspirin and/or non-steroidal antiinflamatory drugs (NSAID). The Triflusal versus Aspirin for the Prevention of Infarction: A Randomized Stroke Study (TAPIRSS) study was performed to explore the efficacy and safety of triflusal versus aspirin in the prevention of vascular complications in patients with a previous TIA or ischemic stroke in a Latin American population. In this pilot study differences between triflusal and aspiring in the prevention of vascular complications after TIA or ischemic stroke were not observed. Hemorrhagic risk was lower with triflusal than with aspirin. The TAPIRSS study contributed evidence on the efficacy and safety of triflusal as a valid alternative to aspirin in the prevention of vascular events in patients with ischemic stroke or TIA.
Key words: antiplatelet agent, aspirin, stroke, transient ischemic attack, triflusal.
Introduction and Overview
Antiplatelet agents represent an important part of the therapeutic armamentarium in the prevention of stroke.
- Type
- Chapter
- Information
- Publisher: Cambridge University PressPrint publication year: 2008
- 1
- Cited by